VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”).  On November 6, 2019 the Company announced that it and others have been sued in the Federal Court of Canada for alleged patent infringement of a stackable modular orbital gardening patent recently issued to Roto-Gro Inc. (https://rqbglobal.com/ravenquest-to-defend-claim-by-roto-gro/).
Today the Company announced that it has served Roto-Gro Inc. with its Statement of Defence and Counterclaim and that the pleading has been filed with the Federal Court.  The Company strenuously denies any infringement of Roto-Gro Inc.’s alleged patent rights and has counterclaimed against Roto-Gro Inc. seeking, among other things, a declaration of invalidity of the recent patent upon which Roto-Gro, Inc. relies.  The Company is also seeking its costs of its defence and counterclaim on a full indemnity basis.RavenQuest has developed and built the intellectual property surrounding its unique Orbital Garden system, and will defend its intellectual property rights to ensure that its business interests are fully protected. RavenQuest will provide further information regarding the material steps in the Roto-Gro Inc. action and counterclaim as they occur.For more information, access RavenQuest’s investor presentation, fact sheet and videos here.Follow RavenQuest:Twitter
Instagram
Facebook
LinkedInAbout RavenQuest BioMed Inc.RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company also focuses on partnerships with Indigenous communities.On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.“George Robinson”
Chief Executive OfficerNeither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking StatementAll statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Bay Street News